Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary) ; Secukinumab (Primary)
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms FUTURE-1
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

  • 28 Dec 2022 Results of pooled analysis (n=1554) of two studies (FUTURE 1 & FUTURE 5) assessing quantify the prevalence and extent of pre-existing radiographic damage at baseline; investigate the association of radiographic damage with swollen/tender joint counts at baseline; and investigate the extent to which RD at baseline correlated with response to secukinumab, published in the Arthritis Research and Therapy.
  • 14 Nov 2022 Serum samples for analyses of proteomics data from FUTURE 1, 3, 4, and 5 studies were presented at the ACR Convergence 2022.
  • 07 Jan 2021 Results of a modelling study from two studies: FUTURE-1(n=539) and FUTURE-5(n=926) assessing predictors of progression and effect of secukinumab on inhibition of structural damage in PsA in subgroups of patients with different underlying rates of progression published in the Clinical and Experimental Rheumatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top